Zobrazeno 1 - 10
of 402
pro vyhledávání: '"Gorraiz M"'
Autor:
Silva-Pilipich N; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain; Nanogrow Biotech, 11500 Montevideo, Uruguay. Electronic address: csmerdou@unav.es., Beloki U; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain., Apaolaza P; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain., Igea A; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain., Salaberry L; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Nanogrow Biotech, 11500 Montevideo, Uruguay., Prats-Mari L; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain., Rovira E; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain., Ondiviela M; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain., Gorraiz M; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain; Immunology and Immunotherapy program, Cima Universidad de Navarra, 31008 Pamplona, Spain., Lasarte JJ; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain; Immunology and Immunotherapy program, Cima Universidad de Navarra, 31008 Pamplona, Spain., Vanrell L; Nanogrow Biotech, 11500 Montevideo, Uruguay. Electronic address: csmerdou@unav.es., Smerdou C; DNA and RNA Medicine division, Cima Universidad de Navarra, 31008 Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdISNA), 31008 Pamplona, Spain. Electronic address: csmerdou@unav.es.
Publikováno v:
Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.
Autor:
Sánchez-Moreno I; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Lasarte-Cia A; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Martín-Otal C; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Casares N; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Navarro F; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Gorraiz M; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Sarrión P; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain., Hervas-Stubbs S; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain.; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain., Jordana L; Hemato-Oncology Program, Centre for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain., Rodriguez-Madoz JR; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain.; Hemato-Oncology Program, Centre for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain., San Miguel J; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain.; Hematology and Cell Therapy Department, Clínica Universidad de Navarra, (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Prosper F; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain.; Hemato-Oncology Program, Centre for Applied Medical Research (CIMA), University of Navarra, IdiSNA, Pamplona, Spain.; Hematology and Cell Therapy Department, Clínica Universidad de Navarra, (CUN), Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Lasarte JJ; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain jjlasarte@unav.es.; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain., Lozano T; Immunology and Immunotherapy Program, Center for Applied Medical Research (CIMA), University of Navarra, IdISNA, Pamplona, Spain.; Cancer Center Universidad de Navarra (CCUN), Pamplona, Spain.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 01; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 01.
Autor:
Martín-Otal, C. (Celia), Lasarte-Cia, A. (Aritz), Serrano-Tejero, D. (Diego), Casares, N. (Noelia), Conde-Gallastegi, E. (Enrique), Navarro-Negredo, F.C. (Flor Cecilia), Sánchez-Moreno, I. (Inés), Gorraiz, M. (Marta), Sarrión, P. (Patricia), Calvo-González, A. (Alfonso), Andrea, C.E. (Carlos Eduardo) de, Echeveste, J.I. (José I.), Vilas, A. (Amaia), Rodriguez-Madoz, J.R. (Juan Roberto), San-Miguel, J.F. (Jesús F.), Prosper, F. (Felipe), Hervas-Stubbs, S. (Sandra), Lasarte, J.J. (Juan José), Lozano-Moreda, T. (Teresa)
Background One of the main difficulties of adoptive cell therapies with chimeric antigen receptor (CAR)-T cells in solid tumors is the identification of specific target antigens. The tumor microenvironment can present suitable antigens for CAR design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1111::7106f96936c49946cad8fef268f039aa
https://hdl.handle.net/10171/64805
https://hdl.handle.net/10171/64805
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Silva-Pilipich N; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Blanco E; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain; Oncoimmunology Research Unit, Navarrabiomed-Universidad Pública de Navarra (UPNA), Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain., Lozano T; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Martisova E; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Igea A; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Herrador-Cañete G; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Ballesteros-Briones MC; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Gorraiz M; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Sarrión P; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., González-Sapienza G; Cátedra de Inmunología, DEPBIO, Facultad de Química, Instituto de Higiene, UDELAR, Montevideo, Uruguay., Lasarte JJ; Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain., Vanrell L; Facultad de Ingeniería, Universidad ORT Uruguay, Montevideo, Uruguay; Nanogrow Biotech, Montevideo, Uruguay. Electronic address: lvanrell@nanogrowbiotech.com., Smerdou C; Division of Gene Therapy and Regulation of Gene Expression, Cima Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdISNA), and CCUN, Pamplona, Spain. Electronic address: csmerdou@unav.es.
Publikováno v:
Cancer letters [Cancer Lett] 2023 May 01; Vol. 561, pp. 216139. Date of Electronic Publication: 2023 Mar 29.
Autor:
Martín-Otal C; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Lasarte-Cia A; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Serrano D; Programa de Tumores sólidos, Centro de Investigación Médica Aplicada, Pamplona, Spain., Casares N; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Conde E; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Navarro F; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Sánchez-Moreno I; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Gorraiz M; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Sarrión P; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain., Calvo A; Programa de Tumores sólidos, Centro de Investigación Médica Aplicada, Pamplona, Spain., De Andrea CE; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.; Departamento de Patología, Clinica Universidad de Navarra, Pamplona, Navarra, Spain., Echeveste J; Departamento de Patología, Clinica Universidad de Navarra, Pamplona, Navarra, Spain., Vilas A; Programa de Hemato-Oncología, Centro de Investigación Médica Aplicada, CIMA, Pamplona, Spain., Rodriguez-Madoz JR; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain; Cancer Center Universidad de Navarra (CCUN), Universidad de Navarra, Pamplona, Spain, San Miguel J; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain; Cancer Center Universidad de Navarra (CCUN), Universidad de Navarra, Pamplona, Spain, Prosper F; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.; Programa de Hemato-Oncología, Centro de Investigación Médica Aplicada, CIMA, Pamplona, Spain.; Centro de Investigacion Biomedica en Red de Cancer (CIBERONC), Madrid, Spain; Cancer Center Universidad de Navarra (CCUN), Universidad de Navarra, Pamplona, Spain, Hervas-Stubbs S; Programa de Inmunología e Inmunoterapia, Centro de Investigación Médica Aplicada, Pamplona, Spain.; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Lasarte JJ; Departamento de Hematología, Clínica Universidad de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain., Lozano T; Departamento de Hematología, Clínica Universidad de Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Publikováno v:
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Aug; Vol. 10 (8).
Autor:
Nakdali Kassab, B., Pérez-Seoane Ballester, H., Sarrió Sanz, P., Sánchez Caballero, L., Gómez Garberí, M., Ortiz Gorraiz, M.
Publikováno v:
In Urology Case Reports September 2022 44
Autor:
Navarro F; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Casares N; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Martín-Otal C; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Lasarte-Cía A; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Gorraiz M; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Sarrión P; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Llopiz D; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Reparaz D; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Varo N; Department of Clinical Biochemistry, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain., Rodriguez-Madoz JR; Program, Center for Applied Medical Research (CIMA), University of Navarra, IdiSNAHemato-Oncology, Pamplona, Spain., Prosper F; Program, Center for Applied Medical Research (CIMA), University of Navarra, IdiSNAHemato-Oncology, Pamplona, Spain.; Department of Hematology, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBERONC, Pamplona, Spain., Hervás-Stubbs S; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Lozano T; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain., Lasarte JJ; Immunology and Immunotherapy Program, University of Navarra, IdiSNA, Pamplona, Spain.
Publikováno v:
Oncoimmunology [Oncoimmunology] 2022 May 01; Vol. 11 (1), pp. 2070337. Date of Electronic Publication: 2022 May 01 (Print Publication: 2022).
Autor:
Lozano T; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain. Electronic address: tlmoreda@unav.es., Conde E; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Martín-Otal C; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Navarro F; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Lasarte-Cia A; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Nasrallah R; Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK., Alignani D; Flow Cytometry Core, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Gorraiz M; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Sarobe P; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Romero JP; Oncohematology Programs, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Vilas A; Oncohematology Programs, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Roychoudhuri R; Laboratory of Lymphocyte Signalling and Development, Babraham Institute, Cambridge, UK; Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK., Hervás-Stubbs S; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Casares N; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain., Lasarte JJ; Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, 31008, IdISNA, Pamplona, Spain. Electronic address: jjlasarte@unav.es.
Publikováno v:
Cancer letters [Cancer Lett] 2022 Mar 01; Vol. 528, pp. 45-58. Date of Electronic Publication: 2021 Dec 29.
Autor:
Xie, Qi1 (AUTHOR), Liu, Xiaolin1 (AUTHOR), Liu, Rengyun2 (AUTHOR), Pan, Jingxuan3 (AUTHOR) panjx2@mail.sysu.edu.cn, Liang, Jing1 (AUTHOR) liangjing0531@163.com
Publikováno v:
Molecular Cancer. 11/12/2024, Vol. 23 Issue 1, p1-37. 37p.